Hepion Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Hepion Pharmaceuticals Inc share price today is $0.17, up -18.79%. The stock opened at $0.385 against the previous close of $0.3916, with an intraday high of $0.414 and low of $0.31.

Hepion Pharmaceuticals Inc Share Price Chart

Hepion Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Hepion Pharmaceuticals Inc Share Price Performance

$0.17 -0.1879(-18.79%) HEPA at 23 Mar 2026 01:26 PM Biotechnology
Lowest Today 0.31
Highest Today 0.414
Today’s Open 0.385
Prev. Close 0.3916
52 Week High 68.00
52 Week Low 0.25
Day’s Range: Low 0.31 High 0.414
52-Week Range: Low 0.25 High 68.00
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -58.16
3 year return -97.71
5 year return -99.25
10 year return -

Hepion Pharmaceuticals Inc Institutional Holdings

Anson Funds Management LP 0.43

BlackRock Inc 0.15

Vanguard Group Inc 0.09

Geode Capital Management, LLC 0.08

Susquehanna International Group, LLP 0.05

Renaissance Technologies Corp 0.03

State Street Corp 0.03

Fidelity Extended Market Index 0.03

UBS Group AG 0.03

PNC Financial Services Group Inc 0.01

Tower Research Capital LLC 0.01

Vanguard Institutional Extnd Mkt Idx Tr 0.01

Morgan Stanley - Brokerage Accounts 0.00

Extended Equity Market Fund K 0.00

Fidelity Series Total Market Index 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Extended Equity Market Fund M 0.00

Federation des caisses Desjardins du Quebec 0.00

Spartan Total Market Index Pool E 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Advisor Group Holdings, Inc. 0.00

Group One Trading, LP 0.00

SBI Securities Co Ltd 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

Bank of America Corp 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

NT Ext Eq Mkt Indx Fd DC Lend T4 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

Barclays PLC 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

BNYM Mellon SL Market Completion UC1 0.00

Hanson Mcclain Inc 0.00

Northern Trust Investments N A 0.00

SignatureFD, LLC 0.00

Hepion Pharmaceuticals Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Hepion Pharmaceuticals Inc Fundamentals

Market Cap 4.30 M

PB Ratio 2.1125

PE Ratio 0.0

Enterprise Value 8.47 M

Total Assets 1.61 M

Volume 4368896

Hepion Pharmaceuticals Inc Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:-67131 -0.1M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-48926042 -48.9M, FY23:-44677888 -44.7M, FY22:-42200049 -42.2M, FY21:-32731027 -32.7M, FY20:-20353938 -20.4M

Quarterly Revenue Q1/2025:null 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:109730 0.1M, Q4/2023:0 0.0M

Quarterly Profit Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M, Q1/2024:-30758 -0.0M, Q4/2023:null 0.0M

Quarterly Net worth Q1/2025:-1547454 -1.5M, Q3/2024:-4865948 -4.9M, Q2/2024:-3925212 -3.9M, Q1/2024:-2853806 -2.9M, Q4/2023:-11059628 -11.1M

About Hepion Pharmaceuticals Inc & investment objective

Company Information Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Hepion Pharmaceuticals Inc FAQs

What is the share price of Hepion Pharmaceuticals Inc today?

The current share price of Hepion Pharmaceuticals Inc is $0.17.

Can I buy Hepion Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Hepion Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Hepion Pharmaceuticals Inc shares in India?

You can easily invest in Hepion Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Hepion Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Hepion Pharmaceuticals Inc?

Hepion Pharmaceuticals Inc has a market cap of $4.30 M.

In which sector does Hepion Pharmaceuticals Inc belong?

Hepion Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Hepion Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Hepion Pharmaceuticals Inc?

The PE ratio of Hepion Pharmaceuticals Inc is N/A and the PB ratio is 2.11.